- 2025, Volume 83 - Number 3
- Published: October 1, 2025
Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases
Gilberto P. da Rosa 1, Isabel Antunes 2, Bárbara V. Granja 3, Patrícia Moreira Gomes 2 
, Rúben Costa 2 , Filomena Azevedo 2 , Alberto Mota 4
1 Department of Dermatology and Venereology, São João Local Health Unit; Department of Medicine, Faculty of Medicine, University of Porto; Porto, Portugal; 2 Department of Dermatology and Venereology, São João Local Health Unit, Porto, Portugal; 3 CINTESIS@RISE, Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal; 4 Department of Dermatology and Venereology, São João Local Health Unit; Department of Medicine, Faculty of Medicine, University of Porto; CINTESIS@RISE, Center for Health Technology and Services Research, Faculty of Medicine, University of Porto. Porto, Portugal
Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Moreira Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Alberto Mota, Email not available
Abstract
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant cutaneous involvement. We present two cases illustrating its beneficial impact in refractory cutaneous lupus erythematosus, including both the subacute and chronic subtypes.
